This study evaluated four umbilical cord blood processing technologies: PrepaCyte-CB, AXP AutoXpress Platform, Sepax, and SLCBB's manual method. Testing found PrepaCyte-CB had significantly higher total nucleated cell and colony-forming unit recoveries post-thaw compared to the other methods. Based on these positive results and minimal impact on operations, the SLCBB initiated an exclusive trial of PrepaCyte-CB to further evaluate product quality from this technology.
Host Cell Protein Analysis by Mass Spectrometry | KBI BiopharmaKBI Biopharma
Host Cell Protein Analysis by Mass Spectrometry. Originally presented at the 2018 Sciex Users Meeting by Michael J Nold, Ph.D., Mass Spectrometry Core Facility at KBI Biopharma.
Host Cell Protein Analysis by Mass Spectrometry | KBI BiopharmaKBI Biopharma
Host Cell Protein Analysis by Mass Spectrometry. Originally presented at the 2018 Sciex Users Meeting by Michael J Nold, Ph.D., Mass Spectrometry Core Facility at KBI Biopharma.
In-silico structure activity relationship study of toxicity endpoints by QSAR...Kamel Mansouri
Several thousand chemicals were tested in hundreds of toxicity-related in-vitro high-throughput screening (HTS)
bioassays through the EPA’s ToxCast and Tox21 projects. However, this chemical set only covers a portion of the chemical
space of interest for environmental risk assessment, leading to a need to fill data gaps with other methods. A cost effective
and reliable approach to fullfill this task is to build quantitative structure-activity relationships (QSARs).
In this work, a subset of 1877 chemicals from ToxCast were used to build QSAR models. These models will be applied
to predict values for multiple ToxCast assays in a larger environmental database of ~30K chemical structures.
Based on a clustering study by Sipes et al. (2013), the initial molecular targets of this effort consisted of a set of 18
NovaScreen G-protein coupled receptor (GPCR) assays. These assays are part of the aminergic category that showed the
highest number of actives within the ToxCast portfolio. Classification methods including SOM, SVM, PLSDA and kNN, were
tested. These methods were coupled to variable selection techniques such as genetic algorithms that were applied in order
to select the best representative molecular descriptors based on statistical fitness functions. The obtained models were
validated and their prediction ability measured. The models that showed good results will be applied within the limits of
their established chemical space defined by the applicability domain.
Evaluation of ctDNA extraction methods and amplifiable copy number yield usin...Thermo Fisher Scientific
The use of cell-free circulating tumor DNA (ctDNA) for non-invasive cancer testing has the potential to revolutionize the field. However, emergence of an increasing number of extraction methods and detection assays is rendering laboratory workflow development much more complex and cumbersome. The use of standardized, well characterized ctDNA control materials in human plasma could facilitate the evaluation of extraction efficiency and assay performance across platforms. In this study, we use a full process ctDNA quality control material in true human plasma to demonstrate the variability of extraction yield between different ctDNA extraction kits. We also examine the correlation between the amplifiable
copy number and DNA concentration post-extraction.
Internal quality control (IQC) in coagulation labAnkit Raiyani
In the haematology laboratory it is essential to ensure that the right test is carried out on the right specimen and that the correct results are delivered to the appropriate recipient without delay.
Quality control (QC) is defined as measures that must be included during each assay run to verify that the test is working properly.
Internal quality control (IQC) is monitoring the haematology test procedures to ensure continual evaluation of the reliability of the daily work of the laboratory with validation of tests before reports are released
Cytochrome P450 enzymes metabolize about 75% of drugs, including oncology drugs, with UGT enzymes metabolizing about another 15%. Variations in gene sequence or in copy number may result in an inactive, defective, unstable, mis-spliced, low expressed, or absent enzyme, an increase in enzyme activity, or an altered affinity for substrates. Pharmacogenomics genes can predict whether an individual is a poor or rapid metabolizer, facilitating dose optimization. Failure to adjust dosage of drugs metabolized by the relevant enzyme can lead to adverse drug reaction, or conversely to too rapid drug metabolism and no drug response. Here, we present a pharmacogenomics (PGx) Research panel to detect 139 SNV/Indel targets in 42 genes (Figure 1) and CYP2D6 copy number variation (CNV, Figure 2). This panel covers the commonly known targets in genes encoding drug metabolism enzymes and associated transport proteins. The panel design is particularly challenging due to high levels of sequence homology between the cytochrome P450 genes. This assay uses Ion AmpliSeq™ technology and contains 146 amplicons in an ultrahigh multiplex PCR in a single pool, followed by Ion Torrent™ semiconductor sequencing. The assay requires as little as 10 ng of input DNA. This customizable panel allows target addition or removal, and will be the first NGS PGx Research panel on the market.
In-silico structure activity relationship study of toxicity endpoints by QSAR...Kamel Mansouri
Several thousand chemicals were tested in hundreds of toxicity-related in-vitro high-throughput screening (HTS)
bioassays through the EPA’s ToxCast and Tox21 projects. However, this chemical set only covers a portion of the chemical
space of interest for environmental risk assessment, leading to a need to fill data gaps with other methods. A cost effective
and reliable approach to fullfill this task is to build quantitative structure-activity relationships (QSARs).
In this work, a subset of 1877 chemicals from ToxCast were used to build QSAR models. These models will be applied
to predict values for multiple ToxCast assays in a larger environmental database of ~30K chemical structures.
Based on a clustering study by Sipes et al. (2013), the initial molecular targets of this effort consisted of a set of 18
NovaScreen G-protein coupled receptor (GPCR) assays. These assays are part of the aminergic category that showed the
highest number of actives within the ToxCast portfolio. Classification methods including SOM, SVM, PLSDA and kNN, were
tested. These methods were coupled to variable selection techniques such as genetic algorithms that were applied in order
to select the best representative molecular descriptors based on statistical fitness functions. The obtained models were
validated and their prediction ability measured. The models that showed good results will be applied within the limits of
their established chemical space defined by the applicability domain.
Evaluation of ctDNA extraction methods and amplifiable copy number yield usin...Thermo Fisher Scientific
The use of cell-free circulating tumor DNA (ctDNA) for non-invasive cancer testing has the potential to revolutionize the field. However, emergence of an increasing number of extraction methods and detection assays is rendering laboratory workflow development much more complex and cumbersome. The use of standardized, well characterized ctDNA control materials in human plasma could facilitate the evaluation of extraction efficiency and assay performance across platforms. In this study, we use a full process ctDNA quality control material in true human plasma to demonstrate the variability of extraction yield between different ctDNA extraction kits. We also examine the correlation between the amplifiable
copy number and DNA concentration post-extraction.
Internal quality control (IQC) in coagulation labAnkit Raiyani
In the haematology laboratory it is essential to ensure that the right test is carried out on the right specimen and that the correct results are delivered to the appropriate recipient without delay.
Quality control (QC) is defined as measures that must be included during each assay run to verify that the test is working properly.
Internal quality control (IQC) is monitoring the haematology test procedures to ensure continual evaluation of the reliability of the daily work of the laboratory with validation of tests before reports are released
Cytochrome P450 enzymes metabolize about 75% of drugs, including oncology drugs, with UGT enzymes metabolizing about another 15%. Variations in gene sequence or in copy number may result in an inactive, defective, unstable, mis-spliced, low expressed, or absent enzyme, an increase in enzyme activity, or an altered affinity for substrates. Pharmacogenomics genes can predict whether an individual is a poor or rapid metabolizer, facilitating dose optimization. Failure to adjust dosage of drugs metabolized by the relevant enzyme can lead to adverse drug reaction, or conversely to too rapid drug metabolism and no drug response. Here, we present a pharmacogenomics (PGx) Research panel to detect 139 SNV/Indel targets in 42 genes (Figure 1) and CYP2D6 copy number variation (CNV, Figure 2). This panel covers the commonly known targets in genes encoding drug metabolism enzymes and associated transport proteins. The panel design is particularly challenging due to high levels of sequence homology between the cytochrome P450 genes. This assay uses Ion AmpliSeq™ technology and contains 146 amplicons in an ultrahigh multiplex PCR in a single pool, followed by Ion Torrent™ semiconductor sequencing. The assay requires as little as 10 ng of input DNA. This customizable panel allows target addition or removal, and will be the first NGS PGx Research panel on the market.
Accelerate Delivery of High Producing Cell LinesMilliporeSigma
Watch the interactive recording here: https://bit.ly/30FTDG0
The quest for a viable upstream process relies on generation of a cell line expressing the protein of interest. Unfortunately, the search for the best-producing clone is often compared with looking for a needle in a haystack. Making this more challenging is the pressure to get it right the first time, quickly and while mitigating risk and costs.
Although a lot of efforts are made on the clonal selection, there is often few to none optimization done on the expression cassette, including promoter and enhancer selection, or signal peptide. The statistical approach on how many clones should be screened to get to a good producer is often overlooked as well.
We combined a new generation of promoters and enhancers to improve strategies on pool and mini pool screening with both CHO-K1 and our own CHOZN® GS which helped deliver high-producing clones in an accelerated timeline. In addition, we are able to begin process development in parallel with cell line development, further reducing timelines.
In this webinar, you will learn:
* How the strategy approach can help reducing the overall timeline of cell line generation
* How we have expanded our platform by designing a completely new vector/cell/process template
* How we have worked on promoters, enhancers, pool/mini-pool approach as well as on timelines from DNA to clone
Watch the interactive recording here: https://bit.ly/30FTDG0
The quest for a viable upstream process relies on generation of a cell line expressing the protein of interest. Unfortunately, the search for the best-producing clone is often compared with looking for a needle in a haystack. Making this more challenging is the pressure to get it right the first time, quickly and while mitigating risk and costs.
Although a lot of efforts are made on the clonal selection, there is often few to none optimization done on the expression cassette, including promoter and enhancer selection, or signal peptide. The statistical approach on how many clones should be screened to get to a good producer is often overlooked as well.
We combined a new generation of promoters and enhancers to improve strategies on pool and mini pool screening with both CHO-K1 and our own CHOZN® GS which helped deliver high-producing clones in an accelerated timeline. In addition, we are able to begin process development in parallel with cell line development, further reducing timelines.
In this webinar, you will learn:
* How the strategy approach can help reducing the overall timeline of cell line generation
* How we have expanded our platform by designing a completely new vector/cell/process template
* How we have worked on promoters, enhancers, pool/mini-pool approach as well as on timelines from DNA to clone
Validation of bevacizumab elisa ich q2 ver3,0 dt14.03krishgen
This document presents a discussion of the characteristics of our KRIBIOLISA™
BEVACIZUMAB ELISA kit considered by us during the validation of this kit in accordance
with ICH Q2 (R1) guidelines. The document is prepared based on tests run in our laboratory
and does not necessarily seek to cover the testing that may be required at user’s end for
registration in, or regulatory submissions. The objective of this validation is to demonstrate
that it is suitable for its intended purpose – detection of Bevacizumab (Avastin)
Quality Criteria Establishment for Dissolution of Ascorbic Acid from Sustaine...CrimsonpublishersNTNF
Quality Criteria Establishment for Dissolution of Ascorbic Acid from Sustained Release Pellets by Mostafa Essam Ahmed Mostafa Eissa in Nutrition and food science open access journal
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Evaluation of ProcessingTechnologies for UCB
1. Evaluation of Processing Technologies for Umbilical Cord Blood (UCB)
Christianna Henderson, Jonathan Wofford, Kathy Fortune, Donna Regan
Saint Louis Cord Blood Bank, SSM Cardinal Glennon Children’s Medical Center
Abstract
Background
Materials & Methods
1
2
An evaluation of three UCB processing technologies was performed to compare product purity
and potency as defined by characterization markers. The technologies were PrepaCyte-CB
(BioE, Minnesota), AXP AutoXpress Platform (GE Healthcare, New Jersey), and Sepax (Biosafe,
Switzerland). These technologies were compared to SLCBB’s manual Hetastarch method.
PrepaCyte-CB is a reagent based two-step manual method requiring centrifugation. The AXP is
an optically controlled device using two-step centrifugation with operator interaction between
steps. Biosafe’s Sepax instrument performs automated cell processing through centrifugation
and optical sensor controlled separation.
To maintain validity of the data comparison, UCB utilized in this study was harvested in 35 ml
CPD anticoagulant, less than 48 hours old, had a minimum volume of 45 mL neat cord blood,
and a minimum TNC of 0.9 x 10e9. Characterization analysis was performed on pre-processing,
post-processing, and post-thaw samples. Testing conditions and methodology were consistent
for all samples. Results are presented below.
Post Processing Characteristics
SLCBB PrepaCyte-CB Sepax AXP
TNC Recovery (%) 86.0 84.0 83.0 78.0
TMNC Recovery (%) 85.5 83.5 84.0 90.5
CD34+ x 106 3.2 4.1 3.5 2.2
CFU x 105 12.0 10.3 11.7 8.7
Trypan Blue (%) 94.0 97.5 98.0 95.0
7-AAD (%) 95.5 97.1 90.6 95.1
Post Thaw Characteristics
SLCBB PrepaCyte-CB Sepax AXP
TNC Recovery (%) 81.8 89.9 85.8 79.7
TMNC Recovery (%) 92.0 87.0 93.0 80.0
CD34Recovery (%) 68.5 76.1 80.8 67.1
CFU Recovery (%) 52.9 80.2 62.7 47.0
Trypan Blue (%) 68.0 72.0 73.0 78.0
7-AAD (%) 48.0 48.2 50.0 95.0
Table 1: Median Post Processing and Post Thaw Comparisons
*N=10 for all processing methods
Conclusion: Prompted by significant CFU and TNC recoveries post thaw, and minimum impact to
operations and capital budget, the SLCBB has initiated a trial with PrepaCyte-CB.
The purpose of this study was to evaluate three emerging technologies for reduction of UCB
units. The three methodologies under evaluation were PrepaCyte-CB (manufactured and
distributed by BioE, Minnesota), AXP AutoXpress Platform (manufactured and distributed by GE
Healthcare, designed by ThermoGenesis) and Sepax (manufactured and distributed by Biosafe,
Switzerland and Biosafe America).
In all business models, it is imperative to be vigilant for opportunities to improve and minimize
time and effort while maximizing output and efficiency. Current processing of UCB at the SLCBB
involves a manual, minimally manipulative technique. In order to expand operations it is critical
to identify a process that will improve current workflow operations for technical staff while
ensuring the production of a quality end product.
The three technologies were evaluated and compared to the current manual technique
• Utilizing consistent equipment, processes and personnel used for routine UCB processing;
• Subjecting the processed UCB to normal cryopreservation temperatures at less than -150ºC;
• Performing a segment study to determine the effects on segment characteristics;
• Thawing the processed UCB according to standard protocol.
• Performing purity, potency and safety testing on the thawed product.
Specimen:
Umbilical Cord Blood Harvest in 35 ml CPD anticoagulant less than 48 hours old. Cord
blood units collected that are unlabeled will be acceptable for processing. For units that do
not make banking criteria, minimum criteria will be 45 mL neat cord blood volume and a TNC
of 0.9 x 10e9 will be utilized to maintain validity of the study. Where it is possible, varying
volumes will be utilized.
A minimum sample size of 10 products per methodology will be evaluated in order to yield a
sufficient population to produce data with a significant statistical outcome. At the point when
10 units have been processed by each method, data will be evaluated against each other
and the current manual methodology. A cost-benefit analysis will also be utilized to
determine which alternate methodology will be fully validated, if any.
Procedure:
Initial samples were taken to determine pre-processing counts. Once processed by the
respective technology, documentation was provided to determine where ancillary samples
could be collected for each technology. Ancillary samples were used to determine the TNC
fraction of each component separated.
The following assays and calculations were performed on each cord blood processed by the
different technologies:
• TNC recovery (pre-processing vs. post-processing)
• MNC recovery
• CD34 enumeration
• CFU assay
• Viability
• Sterility
The following assays and calculations were performed on each segment from the
cryopreserved cord blood unit:
• Trypan Blue Viability
• CFU recovery (segment vs. post-processing)
The following assays and calculations were performed on each thawed cord blood unit:
• TNC recovery (post thaw vs. post processing)
• MNC recovery (post thaw vs. post processing)
• CD34 recovery (post thaw vs. post processing)
• CFU recovery (post thaw vs. post processing)
• Viability
• Sterility
AXP Sepax PrepaCyte-CB SLCBB
AXP Sepax PrepaCyte-CB SLCBB
AXP Sepax SLCBB
Results
AXP Sepax SLCBB
Results (continued)
Post-Thaw TNC Recovery
Mean and Standard Deviation
Post-Thaw CD34+ Recovery
Mean and Standard Deviation
Post-Thaw CFU Recovery
Mean and Standard Deviation
Post-Thaw Viability
Mean and Standard Deviation
Discussion
For statistical analysis, ANOVA was the test applied and significance defined as P<0.05.
All comparative results between the methodologies were unremarkable except for the
following parameters where significance was observed:
Based on the significant post-thaw TNC and CFU recoveries within the PrepaCyte group,
an exclusive trial was initiated to further evaluate the quality of UCB units processed with
this methodology. This decision was also prompted by the fact that major capital
expenditure was not necessitated in transitioning to this technology. The SLCBB is
exploring options for a similar trial with the leading automated technology to directly
compare more significant test groups with the respective methodology.
Post-Evaluation Observations
Results from the trial have supported what was initially seen in the evaluation test group data.
While post-processing TNC recoveries are consistent between PrepaCyte-CB (86%) and the
SLCBB HES method (85%), post-processing WBC recovery has increased from 87% with the
SLCBB HES method to 91% with PrepaCyte-CB.
A thaw control group has been established for PrepaCyte-CB, for comparative purposes moving
forward. Within this group (N=25), mean recoveries are reported as follows:
TNC = 89% (SD = 4%); TMNC = 87% (SD = 6%); CD34+ = 63% (SD = 15%);
CFU = 72% (SD = 14%); TB viability = 71% (SD = 6%).
One parameter of significance between PrepaCyte –CB and all other methodologies initially
evaluated, is hematocrit. PrepaCyte-CB is extremely effective at depleting the RBC fraction at
processing, leading to less RBC contamination post-thaw. Thaw control groups data is reported
as below.
PrepaCyte-CB
PrepaCyte-CB
PrepaCyte (N=25)
HES (N=25)
Average Hct (%) Min. Hct (%) Max. Hct (%)
Pre-processing 35.5
35.2
28.3
26.6
48.4
44.3
Post-Processing 8.2
43.7
2.3
36.4
14.7
49.9
Post-Thaw 3.9
20.6
2.0
13.0
6.7
25.2
PARAMETER COMPARISON P Value
Post-Processing TNC AXP vs. SLCBB <0.01
Post-Thaw TNC Recovery AXP vs. Sepax
AXP vs. PrepaCyte-CB
Sepax vs. SLCBB
PrepaCyte-CB vs. SLCBB
<0.01
<0.001
<0.05
<0.01
Post-Thaw TMNC Recovery AXP vs. Sepax <0.01
Post-Thaw CFU Recovery AXP vs. PrepaCyte-CB
PrepaCyte-CB vs. SLCBB
<0.001
<0.05
Segment CFU Recovery AXP vs. SLCBB
Sepax vs. SLCBB
<0.05
<0.05
Segment Viability AXP vs. Sepax
AXP vs. PrepaCyte-CB
AXP vs. SLCBB
<0.01
<0.05
<0.01
Results
Segment Characteristics
SLCBB PrepaCyte-CB Sepax AXP
CFU Recovery (%) 59.0 54.5 38.5 34.5
Viability (%) (TB) 83.0 82.0 80.5 77.0
Segment Analysis: Although the exact predictive value of segment data is under investigation at
present, segment descriptive data is represented as follows:
Table 2: Median Segment Comparisons
Table 4: Hct Comparison (SLCBB HES vs. PrepaCyte-CB)
Table 3: P values of significance